Clinical trials
Recruiting trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,870 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 8 |
| 2013 | 8 |
| 2014 | 11 |
| 2015 | 5 |
| 2016 | 20 |
| 2017 | 9 |
| 2018 | 28 |
| 2019 | 23 |
| 2020 | 42 |
| 2021 | 87 |
| 2022 | 151 |
| 2023 | 234 |
| 2024 | 326 |
| 2025 | 518 |
| 2026 | 381 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 1,870 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Seoul National University Hospital | 126 |
| Yonsei University | 117 |
| Samsung Medical Center | 98 |
| AstraZeneca | 95 |
| Merck Sharp & Dohme LLC | 68 |
| Asan Medical Center | 48 |
| Novartis Pharmaceuticals | 47 |
| Eli Lilly and Company | 38 |
| Pfizer | 36 |
| Seoul National University Bundang Hospital | 32 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 93 |
| Breast Neoplasms | 89 |
| Neoplasms | 63 |
| Coronary Artery Disease | 56 |
| Stomach Neoplasms | 55 |
| Neoplasm Metastasis | 50 |
| Ovarian Neoplasms | 45 |
| Colorectal Neoplasms | 43 |
| Diabetes Mellitus, Type 2 | 43 |
| Lung Neoplasms | 39 |
Trials
Showing 26 to 50 of 1,870. Each trial links to its page on Pharma Observatory.
1,770 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.